Tg Therapeutics (TGTX) Receivables - Net (2014 - 2026)

Tg Therapeutics' Receivables - Net history runs 8 years deep, the most recent figure standing at $392.0 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 2825.72% year-over-year to $392.0 million; the TTM figure through Mar 2026 stood at $392.0 million (up 2825.72% YoY), while the FY2025 annual figure was $305.6 million, up 136.58% from the prior year.
• Receivables - Net for Q1 2026 stood at $392.0 million, up from $305.6 million in the prior quarter.
• The five-year high for Receivables - Net was $392.0 million in Q1 2026, with the low at $88000.0 in Q2 2022.
• The 5-year median for Receivables - Net is $65.0 million (2024), against an average of $114.6 million.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net sank 90.55% in 2022, then soared 19768.18% in 2023.
• Tg Therapeutics' Receivables - Net stood at $88000.0 in 2022, then surged by 57960.23% to $51.1 million in 2023, then soared by 152.84% to $129.2 million in 2024, then soared by 136.58% to $305.6 million in 2025, then rose by 28.28% to $392.0 million in 2026.
• Business Quant data shows TGTX's Receivables - Net at $392.0 million in Q1 2026, $305.6 million in Q4 2025, and $265.4 million in Q3 2025.